Sökning: WFRF:(Holmqvist Marit) >
Molecular subtyping...
-
Nilsson, CeciliaUppsala universitet,Centrum för klinisk forskning, Västerås,Enheten för onkologi,Vastmanland County Hospital, Sweden
(författare)
Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact
- Artikel/kapitelEngelska2013
Förlag, utgivningsår, omfång ...
-
Informa Healthcare,2013
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-88364
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-88364URI
-
https://doi.org/10.3109/0284186X.2012.711952DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-172675URI
-
https://lup.lub.lu.se/record/3480971URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies|Regional Research Foundation in Uppsala-Orebro||Lions Cancer Foundation||University Hospital, Uppsala||Vastmanlands Research Foundation||
-
Background. Male breast cancer (MBC) is an uncommon disease and there is limited information on the prognostic impact of routinely used clinicopathological parameters. Material and methods. In a retrospective setting, we reviewed 197 MBC patients with accessible paraffin-embedded tumor tissue and clinicopathological data. Immunohistochemical (IHC) stainings were performed on tissue microarrays and histological grading on conventional slides. Cox proportional regression models were applied for uni- and multivariate analyses using breast cancer death as the event. Results. Estrogen receptor (ER) and progesterone receptor positivity were demonstrated in 93% and 77% of patients, respectively. Nottingham histologic grade (NHG) III was seen in 41% and HER2 positivity in 11%. Classification into molecular subtypes using IHC markers according to three alternative definitions revealed luminal A and luminal B in 81% vs. 11%; 48% vs. 44% and 41% vs. 42% of cases. Two cases of basal-like were identified, but no cases of HER2-like. Factors associated with an increased risk of breast cancer death were node positivity (HR 4.5; 95% CI 1.8-11.1), tumor size andgt;20 mm (HR 3.3; 95% CI 1.4-7.9) and ER negativity (HR 10.9; 95% CI 3.2-37.9). No difference in breast cancer death between the luminal subgroups was demonstrated, regardless of definition. Conclusion. MBC tumors were more often of high grade, whereas HER2 overexpression was as frequent as in FBC. Lymph nodes, tumor size and ER status were independent predictors of breast cancer death. The prognostic impact of molecular subtyping in MBC seems to differ from that previously established in FBC.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Johansson, IdaLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University, Sweden(Swepub:lu)med-ijo
(författare)
-
Ahlin, CeciliaDepartment of Oncology, Örebro University Hospital, Örebro, Sweden
(författare)
-
Thorstenson, StenLinköpings universitet,Onkologi,Hälsouniversitetet,Department of Pathology, Linköping University Hospital, Linköping, Sweden(Swepub:liu)steth53
(författare)
-
Amini, Rose-MarieUppsala universitet,Molekylär och morfologisk patologi,Uppsala University, Sweden(Swepub:uu)roseamin
(författare)
-
Holmqvist, MaritUppsala-Örebro Regional Oncologic Center, Uppsala, Sweden
(författare)
-
Bergkvist, LeifUppsala universitet,Centrum för klinisk forskning, Västerås,Lund University, Sweden(Swepub:uu)leber451
(författare)
-
Hedenfalk, IngridLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University, Sweden(Swepub:lu)onk-ifa
(författare)
-
Fjällskog, Marie-LouiseUppsala universitet,Enheten för onkologi,Uppsala University, Sweden(Swepub:uu)marifjal
(författare)
-
Uppsala universitetCentrum för klinisk forskning, Västerås
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Acta Oncologica: Informa Healthcare52:1, s. 102-1090284-186X1651-226X
Internetlänk
Hitta via bibliotek
Till lärosätets databas